Article Archive
Takeda plans to initiate Ph III cetilistat trial, triggers $3M milestone fee to Alizyme
22 September 2008
J&J's epoetin-alfa linked to deaths in stroke trial
22 September 2008
FDA asks Gilead for another clinical study of aztreonam
22 September 2008
Epix receives $500,000 milestone from Foundation
22 September 2008
Barr gets FDA clearance for generic Razadyne
22 September 2008
Pharmatek opens new facility
22 September 2008
BT Pharma closes 2.8M-euro financing
22 September 2008
Laureate adds two new SUBs to capacity
22 September 2008
Cyclacel's sapacitabine enters Ph II trial in MDS
22 September 2008
Trillium secures C$12M financing
22 September 2008
Repligen
22 September 2008
Stock Commentary - Europe - week to Sept 15, 2008
22 September 2008
Benefits of Erbitux in WT-KRAS mCRC tumors highlighted at ESMO
22 September 2008
Stock Commentary - New York week to Sept 15, 2008
22 September 2008
FDA\'s CDER hires 633 new scientists
22 September 2008
PhRMA greets new IP protection law
22 September 2008
B-MS' ipilimumab doubles one-year survival of advanced melanoma patients
22 September 2008
US FTC challenges Fresenius deal
22 September 2008
Cancer Research UK's L333M R&D spend
22 September 2008
UK pharmacy Rx sales fall behind Italy, Canada
22 September 2008
French generic medicine prices cut in 2009
22 September 2008
Three Rivers gets expanded rights to Infergen
22 September 2008
UPDATE: Wyeth's Viviant fails to match Lilly's Evista
22 September 2008
Priorities for breast cancer research identified
22 September 2008
Teva gets EU approval for G-CSF generic
22 September 2008
CEL-SCI to get new manufacturing facility
22 September 2008
Pharma licensing and alliance activity expected to increase
22 September 2008
Regeneron licenses VelocImmune to Columbia Uni
22 September 2008
UK Meningitis Trust highlights ImmBio's vaccine development
22 September 2008
Caelyx plus first-line chemo prolongs PFS in MBC
22 September 2008
Zometa cuts risk of early-stage breast cancer recurrence
22 September 2008
Strong mid-stage data on Pfizer's NSCLC drug
22 September 2008
77% of patients on RAD001 achieve stable pancreatic NET tumors
22 September 2008
Pfizer economic study says Sutent cost effective in mRCC
22 September 2008
FDA bans imports from two Ranbaxy facilities
22 September 2008
Sanofi CEO reshuffle to cost 17M euros
22 September 2008
Guide to better understanding of "the fourth hurdle" - the NICE
22 September 2008
US FTC challenges Fresenius deal
22 September 2008
More antibiotic development needed, warns UK's HPA
22 September 2008
IFPMA launches pediatric task force
22 September 2008
Retail drug sales in year to July 2008
22 September 2008
US
22 September 2008
Study supports palonosetron's delayed phase CINV action
22 September 2008
Over 200 patients enrolled in Generex' Oral-Lyn trial
22 September 2008
Transgene's NSCLC vacc boosts survival after 17 months
22 September 2008
Novartis' RAD001 boosts kidney cancer PFS to five months
22 September 2008
Early-stage vacc eradicates HER2 breast cancer in mice
22 September 2008
UK release for Basilea's Toctino
22 September 2008
Positive data for Novartis' pediatric arthritis treatment
22 September 2008
Teva extends collaboration with Proteologics
22 September 2008
JNCI highlights Epeius' cancer drug Rexin-G
22 September 2008
Mylan's generic Risperdal cleared by FDA
22 September 2008
Charles River buys MIR for $22.5M
22 September 2008
Pfizer launches medicine safety web site
22 September 2008
Bayer tops most-visited European pharma web sites
22 September 2008
Action on Australia's PC report urged by MA
22 September 2008
Kenya fights malaria, HIV, diarrheal disease
22 September 2008
Archimedes buys Fennopharma IP
22 September 2008
Pharmacopeia gets GSK milestone
22 September 2008
Bayer Healthcare acquires Direvo Biotech in 210 million-euro cash deal
22 September 2008
Wyeth's Viviant fails to match Lilly's Evista
22 September 2008
Vit B may protect brain in old age
22 September 2008
China Biopharma effects one for 100 stock split
22 September 2008
World Alzheimer's Day: supporting carers
22 September 2008
CVS Caremark extends tender for Longs
22 September 2008
South Africa starts Prevenar program
22 September 2008
Genta will complete AGENDA enrollment
22 September 2008
Micromet reports on breast cancer trial
22 September 2008
Emergent gets HHS nod for Anthrax vacc contract
22 September 2008
New data published on DOR's orBec
22 September 2008
Stallergenes opens allergen facility
22 September 2008
EpiCept amends deal with Durect
22 September 2008
Polyplus develops new class of modified oligonucleotides
22 September 2008
New Prepandrix data from GSK
22 September 2008
FDA approves Talecris' orphan drug for CIDP
22 September 2008
Novartis' FDA priority review for Coartem
22 September 2008
Cognis starts making vitamin E TPGS aimed at pharmaceutical sector
22 September 2008
Two new indications for Merck & Co's HPV vacc
22 September 2008
Biovitrum pays Amgen initial $130M for drugs
22 September 2008
EPO revokes Genentech/Biogen patent
22 September 2008
Akorn signs ophthalmic contract manufacturing deal
22 September 2008
Zosano sees good results for PTH Patch
22 September 2008
Schering-Plough closes sale of animal health products to Pfizer
22 September 2008
Pay Pharma by its results, says UK Conservative shadow Health Sec
22 September 2008
Takeda reigns supreme among Japanese pharma companies
22 September 2008
Malaria ACT drug price negotiations
22 September 2008
South Africa
22 September 2008
AGI's loss deepens on flat revenue
22 September 2008
Oxford Biomedica's loss narrows but CEO quits
22 September 2008
Penn updates on full-year revenue
22 September 2008
Botox sBLA to be filed for chronic migraine
22 September 2008
Novacea discontinues Asentar after hold lifted
22 September 2008
No big change in 2008 results for Genemedix
22 September 2008
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
